• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Rapport Therapeutics, Inc. - Common Stock (NQ:RAPP)

    36.72 -0.42 (-1.13%)
    Streaming Delayed Price Updated: 3:03 PM EDT, Apr 21, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Rapport Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 Next >
    News headline image
    Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Why Gap Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗
     
    Via Benzinga
    News headline image
    Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
    Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session. 
    Via Chartmill
    News headline image
    Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Participate in Upcoming Investor Conferences
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting
    Poster presentations on Phase 2a trial seizure biomarker, preclinical, and Phase 1 clinical data 
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    This Rapport Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
     
    Via Benzinga
    News headline image
    Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    The 3 Best Healthcare Stocks to Buy in August 2024 ↗
    These are the best healthcare stocks that could bring in massive returns to the investors in the future. Do not miss out on this opportunity. 
    Via InvestorPlace
    News headline image
    RAPP Stock Earnings: Rapport Therapeutics Misses EPS for Q2 2024 ↗
    RAPP stock results show that Rapport Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    News headline image
    Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    3 Under-The-Radar Healthcare Stocks to Buy for Outsized Returns ↗
    These under-the-radar healthcare stocks are on a high growth trajectory and represent companies that recently went public. 
    Via InvestorPlace
    News headline image
    Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain
    Preclinical data on TARPγ8 targeted compound, an analog to Rapport’s lead product candidate RAP-219, demonstrated analgesic activity in multiple pain models 
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Why Contango Ore Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
     
    Via Benzinga
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.